Kinex Pharmaceuticals Receives $40,000,000 New Funding

  • Feed Type
  • Date
    3/6/2014
  • Company Name
    Kinex Pharmaceuticals
  • Mailing Address
    701 Ellicott Street Buffalo, NY 14203
  • Company Description
    Kinex is a specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory diseases.
  • Website
    http://www.kinexpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from this round, coupled with cash on hand, will be used to fund the completion of the commercialization of its oral form of paclitaxel (Oraxol) and irinotecan (Oratecan) in select markets outside of the United States. In addition, the proceeds will fund mid-stage clinical trials in the United States of four of eight Kinex drug candidates.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.